


## AMENDMENTS

1. (Currently Amended) A compound of general formula A-(Y-ONO<sub>2</sub>)<sub>s</sub> (I) and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof, wherein


s is an integer equal to 1;

A is selected from the following β-adrenergic blockers residues of formula (II):




wherein

R<sub>1</sub> is



R<sub>2</sub> is



Z is -C(O)-[.I.];


Z<sub>1</sub> is H;

Y is a bivalent radical having the following meaning selected from the group consisting of:

a)

- straight or branched C<sub>1</sub>-C<sub>20</sub> alkylene being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO<sub>2</sub> or T, wherein T is -OC(O)(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>, -O(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>;

b)



wherein:

n is an integer from 0 to 20,

n<sub>1</sub> is an integer from 1 to 20;


n<sub>2</sub>, n<sub>3</sub>, n<sub>4</sub> and n<sub>5</sub> are integers equal or different from each other, equal to 0 or 1,


R<sup>3</sup> and R<sup>4</sup> are independently selected from H or CH<sub>3</sub>,

Y<sup>1</sup> is -CH<sub>2</sub>- or -(CH<sub>2</sub>)<sub>na</sub>-CH=CH- wherein na is an integer from 0 to 20;

X<sub>1</sub> is -WC(O)- or -C(O)W-, wherein W is oxygen, sulfur or NH; and

c)





(VII)

wherein

X<sub>2</sub> is O or S,

n10a, n10 and n12 are integer independently selected from 0 to 20,

n11 is an integer from 0 to 6;


R<sup>11</sup> is H, CH<sub>3</sub> or nitrooxy group;

R<sup>11a</sup> is CH<sub>3</sub> or nitrooxy group;

and wherein (Y-ONO<sub>2</sub>)<sub>s</sub> bonds with Z and/or [[Z1]] Z<sub>1</sub> of formula (II).

Claims 2-3. (Canceled).

4. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[3]] 1 wherein Y is a straight or branched C<sub>1</sub>-C<sub>10</sub> alkylene.
5. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[2]] 1 wherein Y is



(IV)


wherein


n is an integer from 0 to 20,

n1 is an integer from 1 to 20;

n<sub>2</sub>, n<sub>3</sub>, n<sub>4</sub> and n<sub>5</sub> are integers equal or different from each other, equal to 0 or 1;  
R<sup>3</sup> and R<sup>4</sup> are independently selected from H or CH<sub>3</sub>;  
Y<sup>1</sup> is –CH<sub>2</sub>– or –CH<sub>2</sub>)<sub>na</sub>–CH=CH– wherein na is an integer from 0 to 20;  
X<sub>1</sub> is –WC(O)– or –C(O)W–, wherein W is oxygen, sulfur or NH.

6. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 5 wherein  
n<sub>2</sub>, n<sub>3</sub>, n<sub>4</sub>, n<sub>5</sub> are equal to 0,  
n<sub>1</sub> is 1,  
n is an integer from 0 to 10,  
Y<sup>1</sup> is CH<sub>2</sub>.
7. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 5 wherein  
n, n<sub>2</sub>, n<sub>5</sub> are 1,  
n<sub>3</sub> and n<sub>4</sub> are equal to 0, and  
n<sub>1</sub> is an integer from 1 to 10,  
Y<sup>1</sup> is –(CH<sub>2</sub>)<sub>na</sub>–CH=CH– wherein na is 0,  
X<sub>1</sub> is –WC(O)– wherein W is oxygen and X<sub>1</sub> is bound to the phenyl ring through the [C]<sub>4</sub>,  
R<sup>4</sup> is CH<sub>3</sub> and the group (OR<sup>4</sup>) is bound to the phenyl ring through the [C]<sub>3</sub>.
8. (Currently Amended) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim [[2]] 1 wherein  
Y is





wherein

X<sub>2</sub> is O or S,


n10a, n10 and n12 are integers independently selected from 0 to 20;

n11 is an integer from 0 to 6;

R<sup>11</sup> is H, CH<sub>3</sub> or a nitrooxy group;

R<sup>11a</sup> is CH<sub>3</sub> or a nitrooxy group.

9. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 8 wherein Y is



wherein

X<sub>2</sub> is O or S,

n10a is an integer from 0 to 10

n11 are 0,

n12 is an integer from 1 to 10,

R<sup>11</sup> is H or a nitrooxy group;


wherein the -ONO<sub>2</sub> group is bound to the -(CH<sub>2</sub>)<sub>n12</sub>- group.


Claims 10-57. (Canceled).

58. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 1 wherein Y is a straight or branched C<sub>1</sub>-C<sub>20</sub> alkylene being optionally substituted with one or more of the substituents selected from the group consisting of halogen atoms, hydroxy, -ONO<sub>2</sub> or T, wherein T is -OC(O)(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>, -O(C<sub>1</sub>-C<sub>10</sub>alkyl)-ONO<sub>2</sub>.
59. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to claim 58 wherein Y is a straight or branched C<sub>3</sub>-C<sub>6</sub> alkylene.

Claims 60-80. (Canceled).

81. (Currently Amended) Compounds and the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof according to any one of claims 1, 58 or 59 wherein the compounds are:





Claims 82-87. (Canceled).

88. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts according to claim 1, that is 4-(Nitrooxymethyl)benzoic acid 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanoate.

Claims 89-90. (Canceled).

91. (Previously Presented) A compound and the enantiomers, diastereoisomers and pharmaceutically acceptable salts according to any one of claims 1, 58 or 59, that is 6-(nitrooxy)hexanoic acid 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol hydrochloride.

Claims 92-94. (Canceled).

95. (Currently Amended) A medicament comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 ~~for use as medicament~~.
96. (Currently Amended) A method for the treatment or prophylaxis of hypertension, cardiovascular and vascular diseases using ~~Use of a drug comprising a~~ compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 ~~for preparing a drug that can be employed in the treatment or prophylaxis of hypertension, cardiovascular and vascular diseases~~.
97. (Currently Amended) A method for the treatment of glaucoma and elevated intraocular pressure using ~~Use of a drug comprising a~~ compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 ~~for preparing a drug that can be employed in the treatment of glaucoma and elevated intraocular pressure~~.
98. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) and/or the enantiomers, diastereoisomers and pharmaceutically acceptable salts thereof as defined in ~~any of claims~~ claim 1 to 94 and at least one pharmaceutical pharmaceutically acceptable carrier.